4//SEC Filing
RA Capital Healthcare Fund LP 4
Accession 0001231919-25-000644
CIK 0001817229other
Filed
Dec 18, 7:00 PM ET
Accepted
Dec 19, 6:58 PM ET
Size
13.6 KB
Accession
0001231919-25-000644
Insider Transaction Report
Form 4
RA CAPITAL MANAGEMENT, L.P.
Director10% Owner
Transactions
- Award
Common Stock
2025-12-18$10.81/sh−4,625,346$49,999,990→ 5,404,998 total(indirect: See footnotes) - Award
Stock Option (Right to Buy)
2025-12-18+3,000→ 3,000 total(indirect: See Footnotes)Exercise: $12.80Exp: 2035-12-17→ Common Stock (3,000 underlying)
RA Capital Healthcare Fund LP
Director10% Owner
Transactions
- Award
Common Stock
2025-12-18$10.81/sh−4,625,346$49,999,990→ 5,404,998 total(indirect: See footnotes) - Award
Stock Option (Right to Buy)
2025-12-18+3,000→ 3,000 total(indirect: See Footnotes)Exercise: $12.80Exp: 2035-12-17→ Common Stock (3,000 underlying)
Kolchinsky Peter
Director10% Owner
Transactions
- Award
Common Stock
2025-12-18$10.81/sh−4,625,346$49,999,990→ 5,404,998 total(indirect: See footnotes) - Award
Stock Option (Right to Buy)
2025-12-18+3,000→ 3,000 total(indirect: See Footnotes)Exercise: $12.80Exp: 2035-12-17→ Common Stock (3,000 underlying)
Shah Rajeev M.
Director10% Owner
Transactions
- Award
Common Stock
2025-12-18$10.81/sh−4,625,346$49,999,990→ 5,404,998 total(indirect: See footnotes) - Award
Stock Option (Right to Buy)
2025-12-18+3,000→ 3,000 total(indirect: See Footnotes)Exercise: $12.80Exp: 2035-12-17→ Common Stock (3,000 underlying)
Footnotes (4)
- [F1]RA Capital Management, L.P. (the "Adviser") is the investment manager for RA Capital Healthcare Fund, L.P. (the "Fund"). The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. Each of the Adviser, the Adviser GP, the Fund, Dr. Kolchinsky and Mr. Shah disclaims beneficial ownership of any of the reported securities, except to the extent of its or his respective pecuniary interest therein.
- [F2]Held directly by the Fund.
- [F3]This option was granted to Dr. Andrew Levin pursuant to the Issuer's non-employee director compensation policy. The shares shall vest and become exercisable in a series of 36 successive equal monthly installments beginning on December 18, 2025, in each case subject to Dr. Levin's continued service as of each such date.
- [F4]Under Dr. Levin's arrangement with the Adviser, Dr. Levin holds the option for the benefit of the Fund. Dr. Levin is obligated to turn over to the Adviser any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Adviser. The Reporting Persons therefore disclaim beneficial ownership of the option and underlying common stock.
Documents
Issuer
Vor Biopharma Inc.
CIK 0001817229
Entity typeother
IncorporatedDE
Related Parties
1- filerCIK 0001315082
Filing Metadata
- Form type
- 4
- Filed
- Dec 18, 7:00 PM ET
- Accepted
- Dec 19, 6:58 PM ET
- Size
- 13.6 KB